Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926741 · ClinicalTrials.gov registry record · Early Phase 1
GSNOR Phenotyping/GSNO Challenge in Severe Asthma
A Early Phase 1 study, sponsored by James Reynolds.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
NCT03926741 is a Early Phase 1 study that has completed, run by James Reynolds. The registered enrollment target is 48 participants.
The verdict
NCT03926741, a Early Phase 1 study, has completed, sponsored by James Reynolds.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Asthma is caused by or worsened by different things in different people. It is because of these differences that not all people with asthma respond the same to all treatments and medicines. If the investigators can better identify the changes in the airways or breathing pipes in patients with asthma, the investigators may be able to help patients make better choices about the medicines or treatments that are most likely to work best for each patient. This research study is about one specific factor that is known to affect asthma in some patients. It involves an increase in the activity of an enzyme that is in people's airways. An enzyme is something that helps a chemical reaction to occur. The enzyme the investigators are studying in this research study is called GSNOR (S-nitrosoglutathione reductase) , and when the activity of this enzyme is increased, the result is that there is less GSNO (S-nitrosoglutathione) . GSNO is a chemical that protects people's airways. The initials stand for S-nitrosoglutathione, (pronounced s-nahy-troh-soh-gloo-tuh-thahy-ohn), and it is naturally produced by the body. It has an important role in regulating respiratory function (breathing) and preventing inflammation (swelling) in the respiratory tract (throat, airways, and lungs). The amount of GSNO found in the body is controlled by the enzyme GSNOR (S-nitrosoglutathione reductase). GSNOR breaks down GSNO. Too much GSNOR leads to low levels of GSNO, and that can cause inflammation (swelling) and loss of airway function in some asthma patients. The only way to measure GSNOR levels currently is with a bronchoscopy procedure where a scope is inserted into the patient's airways, often under sedation. This research study is being done to test the accuracy of another type of test that can be done in the doctor's office, rather than in a procedure area. This non-invasive diagnostic test, called a GSNO Challenge test, may be able to identify which asthma patients have increased activity of
Interventions
- DRUG GSNO Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2024-02-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926741
The ClinicalTrials.gov registry entry for NCT03926741 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Reynolds, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSNO Challenge is the first listed.
NCT03926741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926741 about?
NCT03926741 is a clinical study titled "GSNOR Phenotyping/GSNO Challenge in Severe Asthma". Asthma is caused by or worsened by different things in different people. It is because of these differences that not all people with asthma respond the same to all treatments and medicines. If the investigators can better identify the changes in the airways or breathing pipes in patients with asthma...
What is the current status of trial NCT03926741?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2019-04-30. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT03926741?
The interventions under investigation include: GSNO Challenge (DRUG).
Who is sponsoring clinical trial NCT03926741?
This trial is sponsored by James Reynolds, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.